![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Court: Hospira Wasn’t Protected by Safe Harbor in $70 Million Biosimilars Case
Court: Hospira Wasn’t Protected by Safe Harbor in $70 Million Biosimilars Case
October 5, 2018
A federal court in Delaware refused to undo a 2017 decision awarding $70 million to Amgen in its patent infringement battle with Hospira.
Last September, a federal jury found that Hospira’s biosimilar for Epogen (epoetin alfa), a treatment for anemia caused by chronic kidney disease, violated a key Amgen patent. In the initial trial, Hospira argued it needed its batches of the drug as part of the FDA’s approval process for biosimilars.
Hospira moved for a judgment that producing biosimilar batches is protected under safe harbor—and that it didn’t owe damages greater than $1.5 million per batch of drugs later sold.
Upcoming Events
-
21Oct